Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Romero, Rodrigo, Sayin, Volkan I, Davidson, Shawn M, Bauer, Matthew R, Singh, Simranjit X, LeBoeuf, Sarah E, Karakousi, Triantafyllia R, Ellis, Donald C +20 more·2017·Nature Medicine

DOI 10.1038/nm.4407

Cited by (664)

Items 101–200 of 664

Clinical development of metabolic inhibitors for oncology
Kathryn M. Lemberg, Sadakatali S. Gori, Takashi Tsukamoto, Rana Rais, Barbara S. Slusher · 2022 · Journal of Clinical Investigation
Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer
Yun Pyo Kang, Laura Torrente, Aimee Falzone, Cody M. Elkins, Min Liu, John M. Asara, Christian C. Dibble, Gina M. DeNicola · 2019 · eLife
Regulation of antioxidants in cancer
Fábio Hecht, Marco Zocchi, Fatemeh Alimohammadi, Isaac S. Harris · 2023 · Molecular Cell
Argonaute proteins: Structural features, functions and emerging roles
Jin’en Wu, Jing Yang, William Chi Shing Cho, Yadong Zheng · 2020 · Journal of Advanced Research
5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA -Mutant Colorectal Cancers
Yiqing Zhao, Xiujing Feng, Yicheng Chen, Jennifer Eva Selfridge, Shashank Gorityala, Zhanwen Du, Janet M. Wang, Yujun Hao, Gino Cioffi, Ronald A. Conlon et al. · 2020 · Cancer Research
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, Haitang, Liang, Shun-Qing, Schmid, Ralph A., Peng, Ren-Wang · 2019 · Frontiers in Oncology
Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation
Antoinette van Weverwijk, Nikos Koundouros, Marjan Iravani, Matthew Ashenden, Qiong Gao, George Poulogiannis, Ute Jungwirth, Clare M. Isacke · 2019 · Nature Communications
Role of NRF2 in Lung Cancer
Miriam Sánchez-Ortega, Ana Clara Carrera, António Garrido · 2021 · Cells
Glutamine deprivation alters the origin and function of cancer cell exosomes
Fan, Shih‐Jung, Kroeger, Benjamin, Marie, Pauline P, Bridges, Esther M, Mason, John D, McCormick, Kristie, Zois, Christos E, Sheldon, Helen, Khalid Alham, Nasullah, Johnson, Errin et al. · 2020 · The EMBO Journal
Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies
Alexander Muir, Laura V. Danai, Matthew G. Vander Heiden · 2018 · Disease Models & Mechanisms
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Haiyang Guo, Jun Zhang, Chao Qin, Hang Yan, Tao Liu, Haiyang Hu, Shengjie Tang, Shoujun Tang, Haining Zhou · 2022 · Cells
Metabolic Regulation of Redox Balance in Cancer
Vinee Purohit, Diane M. Simeone, Costas Andreas Lyssiotis · 2019 · Cancers
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
Giorgia Foggetti, Chuan Li, Hongchen Cai, Jessica A. Hellyer, Wen-Yang Lin, Deborah O. Ayeni, Katherine Hastings, Jungmin Choi, Anna Wurtz, Laura Andrejka et al. · 2021 · Cancer Discovery
Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma
Best, Sarah A., Ding, Sheryl, Kersbergen, Ariena, Dong, Xueyi, Song, Ji-Ying, Xie, Yi, Reljic, Boris, Li, Kaiming, Vince, James E., Rathi, Vivek et al. · 2019 · Nature Communications
EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion
Antonio Marzio, Emma Kurz, Jennifer M. Sahni, Giuseppe Di Feo, Joseph Puccini, Shaowen Jiang, Carolina Alcantara Hirsch, Arnaldo Arbini, Warren Wu, Harvey Ira Pass et al. · 2021 · Cell
The m 6 A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor
Yiren Xiao, Kaushik N. Thakkar, Hongjuan Zhao, James P. Broughton, Yang Li, José Antonio Seoane, Anh N. Diep, Thomas J. Metzner, Rie von Eyben, David L. Dill et al. · 2020 · Proceedings of the National Academy of Sciences
TrxR1, Gsr, and oxidative stress determine hepatocellular carcinoma malignancy
Michael McLoughlin, David J. Orlicky, Justin R. Prigge, Pushya Krishna, Emily A. Talago, Ian Cavigli, Sofi E. Eriksson, Colin G. Miller, Jean A. Kundert, Volkan I. Sayin et al. · 2019 · Proceedings of the National Academy of Sciences
DPP9 Stabilizes NRF2 to Suppress Ferroptosis and Induce Sorafenib Resistance in Clear Cell Renal Cell Carcinoma
Kun Sang Chang, Yingji Chen, Xuanzhi Zhang, Wei Zhang, Ning Xu, Bohan Zeng, Yue Wang, Tao Feng, Bo Dai, Fujiang Xu et al. · 2023 · Cancer Research
Starve Cancer Cells of Glutamine: Break the Spell or Make a Hungry Monster?
Jie Jiang, Sankalp Srivastava, Ji Zhang · 2019 · Cancers
Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells
Sujin Lee, Steffanus Pranoto Hallis, Kyeong-Ah Jung, Da-Young Ryu, Mi‐Kyoung Kwak · 2019 · Redox Biology
The role of glutamate and glutamine metabolism and related transporters in nerve cells
Dongyang Zhang, Zhongyan Hua, Zhijie Li · 2024 · CNS Neuroscience & Therapeutics
Discovery of IPN60090, a Clinical Stage Selective Glutaminase‑1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties
Michael Soth, Kang Le, Maria Emilia Di Francesco, Matthew M. Hamilton, Gang Liu, Jason P. Burke, Christopher L. Carroll, Jeffrey J. Kovacs, Jennifer Bardenhagen, Christopher Aaron Bristow et al. · 2020 · Journal of Medicinal Chemistry
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies
Mariacarmela Santarpía, Andrés Aguilar, Imane CHAIB-OUKADOUR, Andrés Felipe Cardona, Sara Fancelli, Fernando Laguía, Jillian Wilhelmina Paulina Bracht, Peng Cao, Miguel Ángel Molina‐Vila, Niki Karachaliou et al. · 2020 · Cancers
Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer
Lynette Marie Sholl · 2021 · Modern Pathology
The A to Z of modulated cell patterning by mammalian thioredoxin reductases
Markus Dagnell, Edward E. Schmidt, Elias S.J. Arnér · 2017 · Free Radical Biology and Medicine
Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition
Hongyu Ding, Zihong Chen, Katherine Wu, Shih Ming Huang, Warren Wu, Sarah E. LeBoeuf, Ray Pillai, Joshua D. Rabinowitz, Thales Y. Papagiannakopoulos · 2021 · Science Advances
Glutaminase isoenzymes in the metabolic therapy of cancer
José Manuel Matés, José Angel Campos-Sandoval, Javier Márquez · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
The NRF2/KEAP1 Axis in the Regulation of Tumor Metabolism: Mechanisms and Therapeutic Perspectives
Emiliano Panieri, Pelin Telkoparan‐Akillilar, Síbel Süzen, Luciano Saso · 2020 · Biomolecules
Enhancer remodeling promotes tumor-initiating activity in NRF2-activated non-small cell lung cancers
Keito Okazaki, Hayato Anzawa, Zun Liu, Nao Ota, Hiroshi Kitamura, Yoshiaki Onodera, Md. Morshedul Alam, Daisuke Matsumaru, Takuma Suzuki, Fumiki Katsuoka et al. · 2020 · Nature Communications
Defining a metabolic landscape of tumours: genome meets metabolism
Chandan Seth Nanda, Sharavan Vishaan Venkateswaran, Neill Patani, Mariia O. Yuneva · 2019 · British Journal of Cancer
Nuclear Factor Erythroid 2-Related Factor 2 in Regulating Cancer Metabolism
Katarína Smolková, Edit Mikó, Tündé Kovàcs, Alberto Leguina‐Ruzzi, Adrienn Sipos, Péter Bai · 2020 · Antioxidants and Redox Signaling
A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
James J. Harding, Melinda L. Telli, Pamela N. Münster, Martin Henner Voss, Jeffrey R. Infante, Angela M. DeMichele, Mark P. Dunphy, Mai Hope Le, Chris Molineaux, Keith William Orford et al. · 2021 · Clinical Cancer Research
Combinatorial CRISPR-Cas9 Metabolic Screens Reveal Critical Redox Control Points Dependent on the KEAP1-NRF2 Regulatory Axis
Dongxin Zhao, Mehmet G. Badur, Jens Luebeck, Jose H. Magaña, Amanda Birmingham, Roman Šášik, Christopher S. Ahn, Trey Ideker, Christian M. Metallo, Prashant Mali · 2018 · Molecular Cell
The KEAP1-NRF2 System in Healthy Aging and Longevity
Daisuke Matsumaru, Hozumi Motohashi · 2021 · Antioxidants
Vimentin is required for tumor progression and metastasis in a mouse model of non–small cell lung cancer
Alexandra L. Berr, Kristin M. Wiese, Gimena dos Santos, Clarissa M. Koch, Kishore Reddy Anekalla, Martha E. Kidd, Jennifer M. Davis, Yuan Cheng, Yuan‐Shih Hu, Karen M. Ridge · 2023 · Oncogene
Targeting FSP1 triggers ferroptosis in lung cancer
Katherine Wu, Alec J. Vaughan, Jozef P. Bossowski, Yuan Hao, Aikaterini Ziogou, Seon Min Kim, Tae Ha Kim, Mari N. Nakamura, Ray Pillai, Mariana Camargo Silva Mancini et al. · 2025 · Nature
HSP90: Enabler of Cancer Adaptation
Alex M. Jaeger, Luke J. Whitesell · 2018 · Annual Review of Cancer Biology
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, Xiujuan Qu · 2024 · Biomedicine & Pharmacotherapy
Glutaminases regulate glutathione and oxidative stress in cancer
Matés, José M., Campos-Sandoval, José A., de los Santos-Jiménez, Juan, Márquez, Javier · 2020 · Archives of Toxicology
NRF2 signalling in cytoprotection and metabolism
Shohei Murakami, Yusuke Kusano, Keito Okazaki, Takaaki Akaike, Hozumi Motohashi · 2023 · British Journal of Pharmacology
Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State
Anneleen Daemen, Bonnie Liu, Kyung Song, Mandy Kwong, Min Gao, Rebecca Hong, Michelle Nannini, David Peterson, Bianca M. Liederer, Cecile de la Cruz et al. · 2018 · Cell Metabolism
Molecular mechanisms of oxidative stress in stroke and cancer
Vishal K. Chavda, Bipin Kumar Chaurasia, Kanwaljeet Garg, Harsh Deora, Giuseppe Emmanuele Umana, Paolo Palmisciano, Gianluca Scalia, Bingwei Lu · 2021 · Brain Disorders
CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives
Yau-Tuen Chan, Yuanjun Lu, Junyu Wu, Cheng Zhang, Hor‐Yue Tan, Zhaoxiang Bian, Ning Wang, Yibin Feng · 2022 · Theranostics
“NRF2 addiction” in lung cancer cells and its impact on cancer therapy
Ahmed Hammad, Akhileshwar Namani, Mohamed Elshaer, Xiu Jun Wang, Xiuwen Tang · 2019 · Cancer Letters
Synthetic Lethality and Cancer – Penetrance as the Major Barrier
Colm J. Ryan, Ilirjana Bajrami, Christopher J. Lord · 2018 · Trends in cancer
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation
Gong, Meiling, Li, Yan, Ye, Xiaoping, Zhang, Linlin, Wang, Zhifang, Xu, Xiaowen, Shen, Yejing, Zheng, Cuixia · 2020 · Cell Communication and Signaling
Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma
Frauke Goeman, Francesca De Nicola, Stefano Scalera, Francesca Sperati, Enzo Gallo, Ludovica Ciuffreda, Matteo Pallocca, Laura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi et al. · 2019 · Journal of Thoracic Oncology
Targeting extracellular nutrient dependencies of cancer cells
Javier García‐Bermúdez, Robert T. Williams, Rohiverth Guarecuco, Kıvanç Birsoy · 2019 · Molecular Metabolism
Hyperactivity of the transcription factor Nrf2 causes metabolic reprogramming in mouse esophagus
Junsheng Fu, Zhaohui Xiong, Caizhi David Huang, Jing Li, Wenjun Yang, Yuning Han, Chorlada Paiboonrungruan, Michael B. Major, Ke‐Neng Chen, Xiaozheng Kang et al. · 2018 · Journal of Biological Chemistry
NRF2 and the Ambiguous Consequences of Its Activation during Initiation and the Subsequent Stages of Tumourigenesis
Holly Robertson, Albena T. Dinkova‐Kostova, John D. Hayes · 2020 · Cancers
Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research
Aikseng Ooi · 2019 · Seminars in Cancer Biology
Dissecting the Crosstalk between NRF2 Signaling and Metabolic Processes in Cancer
Janine M. DeBlasi, Gina M. DeNicola · 2020 · Cancers
Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC
Jessica A. Hellyer, Sukhmani Kaur Padda, Maximilian Diehn, Heather A. Wakelee · 2020 · Journal of Thoracic Oncology
CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment
Bin Liu, Ali Saber, Hidde J. Haisma · 2019 · Drug Discovery Today
Complex synthetic lethality in cancer
Colm J. Ryan, Lovely Jael Paul Solomon Devakumar, Stephen J. Pettitt, Christopher J. Lord · 2023 · Nature Genetics
A Glutaminase Isoform Switch Drives Therapeutic Resistance and Disease Progression of Prostate Cancer
Lingfan Xu, Yu Yin, Yanjing Li, Xufeng Chen, Yan Chang, Hong Zhang, Juan Liu, James Beasley, Patricia McCaw, Haoyue Zhang et al. · 2020 · Proceedings of the National Academy of Sciences
Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer
Ray Pillai, Sarah E. LeBoeuf, Yuan Hao, Connie New, Jenna L. E. Blum, Ali Rashidfarrokhi, Shih Ming Huang, Christian Bahamon, Warren Wu, Burcu Karadal-Ferrena et al. · 2024 · Science Advances
CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer
Sheng Rong Ng, William M. Rideout, Elliot H. Akama‐Garren, Arjun J. Bhutkar, Kim L. Mercer, Jason M. Schenkel, Roderick Terry Bronson, Tyler Jacks · 2019 · Proceedings of the National Academy of Sciences
Ubiquitin ligases in cancer: Functions and clinical potentials
Shanshan Duan, Michele Pagano · 2021 · Cell chemical biology
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1
Rodrigo Romero, Francisco J. Sánchez Rivera, Peter M.K. Westcott, Kim L. Mercer, Arjun J. Bhutkar, Alexander Muir, Tania J González-Robles, Swanny Lamboy Rodríguez, Laura Z. Liao, Sheng Rong Ng et al. · 2020 · Nature Cancer
Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks
Ke Xu, Jie Ma, Sean R. R. Hall, Ren‐Wang Peng, Haitang Yang, Feng Yao · 2023 · Theranostics
Nrf2 as a regulator of energy metabolism and mitochondrial function
Alina Yu. Luchkova, Ana Mata, Susana Cadenas · 2024 · FEBS Letters
Interplay of oxidative stress and antioxidant mechanisms in cancer development and progression
Klaudia Jomová, Suliman Yousef Alomar, Richard Valko, Lukas Fresser, Eugenie Nepovimová, Kamil Kuča, Marián Valko · 2025 · Archives of Toxicology
KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub
Stefano Scalera, Marco Mazzotta, Clelia Cortile, Eriseld Krasniqi, Ruggero D. Maria, Federico Cappuzzo, Gennaro Ciliberto, Marcello Maugeri‐Saccà · 2022 · Journal of Thoracic Oncology
Sirpiglenastat (DRP-104) Induces Antitumor Efficacy through Direct, Broad Antagonism of Glutamine Metabolism and Stimulation of the Innate and Adaptive Immune Systems
Yumi Yokoyama, Thomas M. Estok, Robert Wild · 2022 · Molecular Cancer Therapeutics
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer
Éabha O’Sullivan, Anna Keogh, Brian Henderson, Stephen P. Finn, Steven G. Gray, Kathy A. Gately · 2023 · Cancers
Tumor microenvironmental nutrients, cellular responses, and cancer
Graham P. Lobel, Yanqing Jiang, Marie Celeste Simon · 2023 · Cell chemical biology
KEAP1 deficiency drives glucose dependency and sensitizes lung cancer cells and tumors to GLUT inhibition
Pranavi Koppula, Kellen L. Olszewski, Yilei Zhang, Lavanya Kondiparthi, Xiaoguang Liu, Guang Lei, Molina Das, Bingliang Fang, Masha V. Poyurovsky, Boyi Gan · 2021 · iScience
Contribution of NRF2 to sulfur metabolism and mitochondrial activity
Md. Morshedul Alam, Akihiro Kishino, Eunkyu Sung, Hiroki Sekine, Takaaki Abe, Shohei Murakami, Takaaki Akaike, Hozumi Motohashi · 2023 · Redox Biology
KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy
Stefano Scalera, Marco Mazzotta, Giacomo Corleone, Francesca Sperati, Irene Terrenato, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Patrizia Vici, Enzo Gallo et al. · 2021 · Journal of Thoracic Oncology
Deregulated transcription factors in cancer cell metabolisms and reprogramming
Rajni Kant, Rajesh Manne, Mohammad Anas, Vasudevarao Penugurti, Tingjin Chen, Bo‐Syong Pan, Che-Chia Hsu, Hui‐Kuan Lin · 2022 · Seminars in Cancer Biology
Nrf2 Mediates Metabolic Reprogramming in Non-Small Cell Lung Cancer
Jiangang Zhao, Lin Xu, Di Meng, Liping Zeng, Runzhou Zhuang, Sha Huang, Wang Lv, Jian Hu · 2020 · Frontiers in Oncology
Glutathione-Dependent Pathways in Cancer Cells
Elena V. Kalinina · 2024 · International Journal of Molecular Sciences
Targeting KRAS: from metabolic regulation to cancer treatment
Yanyan Shi, Huiling Zheng, Tianzhen Wang, Shengpu Zhou, Shiqing Zhao, Mo Li, Baoshan Cao · 2025 · Molecular Cancer
Comprehensive Review of Methodology to Detect Reactive Oxygen Species (ROS) in Mammalian Species and Establish Its Relationship with Antioxidants and Cancer
Shivkanya Fuloria, Vetriselvan Subramaniyan, Karupiah Sundram, Usha Kumari, Kathiresan V. Sathasivam, Dhanalekshmi Unnikrishnan Meenakshi, Yuan Seng Wu, Mahendran Sekar, Nitin Chitranshi, Rishabha Malviya et al. · 2021 · Antioxidants
Determinants of nutrient limitation in cancer
Mark R. Sullivan, Matthew G. Vander Heiden · 2019 · Critical Reviews in Biochemistry and Molecular Biology
The Pleiotropic Role of the KEAP1/NRF2 Pathway in Cancer
Warren Wu, Thales Y. Papagiannakopoulos · 2020 · Annual Review of Cancer Biology
Recent advances in preclinical models for lung squamous cell carcinoma
Yuanwang Pan, Han Han, Kristen E. Labbe, Hua Zhang, Kwok‐Kin Wong · 2021 · Oncogene
Pharmacological Applications of Nrf2 Inhibitors as Potential Antineoplastic Drugs
Pelin Telkoparan‐Akillilar, Síbel Süzen, Luciano Saso · 2019 · International Journal of Molecular Sciences
SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1–Negative Lung Adenocarcinomas
Ichidai Tanaka, Delphine Daydé, Mei-Chee Tai, Haruki Mori, Luisa Maren Solis, S. C. Tripathi, Johannes Francois Fahrmann, Neşe Ünver, Gargy Parhy, Rekha Jain et al. · 2021 · JNCI Journal of the National Cancer Institute
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Heng‐Chung Kung, Kevin Zheng, Jacquelyn W. Zimmerman, Lei Zheng · 2025 · Nature Reviews Clinical Oncology
NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
Li Guan, Dhanya K. Nambiar, Hongbin Cao, Vignesh Viswanathan, Shirley Kwok, Angela Bik‐Yu Hui, Yuan Hou, Rachel Hildebrand, Rie von Eyben, Brittany Holmes et al. · 2023 · Cancer Research
Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design
Jonathan Wesley Riess, Paul Henry Frankel, David B. Shackelford, Mark P. Dunphy, Ramsey Derek Badawi, Lorenzo Nardo, Simon R. Cherry, Ian R. Lanza, Joel M. Reid, Wilson I. Gonsalves et al. · 2020 · Clinical Lung Cancer
Disulfidptosis: a novel cell death modality induced by actin cytoskeleton collapse and a promising target for cancer therapeutics
Tianyi Li, Ying Song, Lijuan Wei, Xiangyi Song, Ruifeng Duan · 2024 · Cell Communication and Signaling
Recent advances in cancer metabolism: a technological perspective
Yun Pyo Kang, Nathan P. Ward, Gina M. DeNicola · 2018 · Experimental & Molecular Medicine
CRISPR/Cas9 genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib, and regorafenib sensitivity gene in hepatocellular carcinoma
A. Zheng, Nadja Chevalier, Margot Calderoni, Gilles Dubuis, O. Dormond, Panos G. Ziros, G. Sykiotis, C. Widmann · 2019 · OncoTarget
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
Meichen Gu, Tiankai Xu, Pengyu Chang · 2021 · Therapeutic Advances in Medical Oncology
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Anne-Laure Désage, Camille Léonce, Aurélie Swalduz, Sandra Ortiz‐Cuaran · 2022 · Frontiers in Oncology
A Multimodal Knowledge-enhanced Whole-slide Pathology Foundation Model
Xu, Yingxue, Wang, Yihui, Zhou, Fengtao, Ma, Jiabo, Jin, Cheng, Yang, Shu, Li, Jinbang, Zhang, Zhengyu, Zhao, Chenglong, Zhou, Huajun et al. · 2024 · arXiv
Targeting Nrf2 may reverse the drug resistance in ovarian cancer
Danjie Li, Xiaoling Hong, Feijie Zhao, Xinxin Ci, Songling Zhang · 2021 · Cancer Cell International
A multimodal knowledge-enhanced whole-slide pathology foundation model
Yingxue Xu, Yihui Wang, Fengtao Zhou, Jiabo Ma, Cheng Jin, Shu Yang, Jinbang Li, Zhengyu Zhang, Chenglong Zhao, Huajun Zhou et al. · 2025 · Nature Communications
Applications of CRISPR/Cas9 Technology in the Treatment of Lung Cancer
Chunyang Jiang, Xiaohui Lin, Zhigang Zhao · 2019 · Trends in Molecular Medicine
Frontiers in cancer immunotherapy—a symposium report
Jennifer Cable, Benjamin D. Greenbaum, Dana Pe’er, Catherine M. Bollard, Sofía Bruni, Matthew E. Griffin, James Patrick Allison, Catherine J. Wu, Sumit Kumar Subudhi, Elaine R. Mardis et al. · 2020 · Annals of the New York Academy of Sciences
Reactive oxygen species control protein degradation at the mitochondrial import gate
Rachael A. McMinimy, Andrew G. Manford, Christine L. Gee, Srividya Chandrasekhar, Gergey Alzaem Mousa, Joelle Chuang, Lilian Phu, Karen Y. Shih, Christopher M. Rose, John Kuriyan et al. · 2024 · Molecular Cell
Polyamine pathway activity promotes cysteine essentiality in cancer cells
Tong Zhang, Christin Bauer, Alice C. Newman, Alejandro Huerta Uribe, Dimitris Athineos, Karen Blyth, Oliver D.K. Maddocks · 2020 · Nature Metabolism
In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma
Akash Kaushik, Amy Tarangelo, Lindsey K. Boroughs, Mukundan Ragavan, Yuanyuan Zhang, Cheng‐Yang Wu, Xiangyi Li, Kristen Ahumada, Jui‐Chung Chiang, Vanina Toffessi Tcheuyap et al. · 2022 · Science Advances
Metabolic features of cancer cells in NRF2 addiction status
Okazaki, Keito, Papagiannakopoulos, Thales, Motohashi, Hozumi · 2020 · Biophysical Reviews
Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2
Liam Baird, Takafumi Suzuki, Yu Takahashi, Eiji Hishinuma, D. Saigusa, M. Yamamoto · 2020 · Molecular and Cellular Biology
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Ingvild Comfort Hvinden, Tom A.D. Cadoux-Hudson, Christopher John Schofield, James McCullagh · 2021 · Cell Reports Medicine
Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors
Makiko Hayashi, Ayumi Kuga, Mikiko Suzuki, Harit Panda, Hiroshi Kitamura, Hozumi Motohashi, Masayuki P. Yamamoto · 2020 · Cancer Research